Trevi Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Trevi Therapeutics has a total shareholder equity of $72.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $78.6M and $6.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$72.82m |
Equity | US$72.33m |
Total liabilities | US$6.23m |
Total assets | US$78.56m |
Recent financial health updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Recent updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Trevi adds 19% on full data set from mid-stage cough study
Sep 19Trevi Therapeutics: Moving Forward
Sep 11Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Trevi has a new development chief
Feb 01Financial Position Analysis
Short Term Liabilities: TRVI's short term assets ($76.8M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: TRVI's short term assets ($76.8M) exceed its long term liabilities ($949.0K).
Debt to Equity History and Analysis
Debt Level: TRVI is debt free.
Reducing Debt: TRVI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRVI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TRVI has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 10% each year.